BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study | Chemically-Induced Disorders, Stress Disorders, Traumatic, acute stress disorder, alcohol-related disorders, post-traumatic stress disorder, psychiatric disorder, substance-related disorder | Recruiting | Phase 1 | 2026-09-21 | NCT06335407 | |
| BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT05558982 | |
| Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder | Bipolar and Related Disorders, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, bipolar disorder, mood disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 1 | 2026-08-11 | NCT05025605 | |
| Sublingual Dexmedetomidine for Treating Opioid Withdrawal | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-14 | NCT05712707 |